| 產(chǎn)品編號(hào) | bs-0170R-BF350 |
| 英文名稱 | Rabbit Anti-VEGFR1/BF350 Conjugated antibody |
| 中文名稱 | BF350標(biāo)記的血管內(nèi)皮生長(zhǎng)因子受體1抗體 |
| 別 名 | VEGF-R1; VEGFR-1; VEGF Receptor 1; FLT-1; vascular permeability factor receptor; vascular endothelial growth factor receptor; vascular endothelial growth factor receptor-1; fms-related tyrosine kinase 1; vascular endothelial growth factor/vascular permeability factor receptor; AI323757; FLT; FLT1; sFlt1; VGFR1_HUMAN; VGFR1_MOUSE. |
| 規(guī)格價(jià)格 | 100ul/2980元 購買 大包裝/詢價(jià) |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 發(fā)育生物學(xué) 神經(jīng)生物學(xué) 生長(zhǎng)因子和激素 激酶和磷酸酶 細(xì)胞膜受體 細(xì)胞表面分子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Mouse, Rat, (predicted: Human, Pig, Horse, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 147kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from mouae VEGFR1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: VEGF Receptor 1 (also known as FLT) belongs to the src gene family and shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation. The protein acts as a receptor for VEGF, VEGFB and PGF. An alternatively spliced form of the gene produces a soluble protein (sFlt1) which binds vascular endothelial growth factor (VEGF) with high affinity. sFlt1 has a higher affinity for VEGF indicating that it may function as an inhibitor in the VEGF response. VEGF Receptor 1 is specifically expressed in most vascular endothelial cells and peripheral blood monocytes. Function: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, and proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts. Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to the activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates PLCG1. Promotes phosphorylation of AKT1, PTK2/FAK1; YES1 and CBL. Subunit: Interacts with VEGFA, VEGFB and PGF. Monomer in the absence of bound VEGFA, VEGFB or PGF. Homodimer in the presence of bound VEGFA, VEGFB and PGF. Can also form a heterodimer with KDR.Interacts (when tyrosine phosphorylated) with CBL, CRK, GRB2, NCK1,PIK3R1, PLCG1 and PTPN11. Interacts with GNB2L1/RACK1. Identified in a complex with CBL and CD2AP. Subcellular Location: Isoform 1: Cell membrane; Single-pass type I membrane protein. Endosome. Note=Autophosphorylation promotes ubiquitination and endocytosis；Isoform 2: Secreted；Isoform 3: Secreted；Isoform 4: Secreted；Isoform 5: Cytoplasm (Potential)；Isoform 6: Cytoplasm (Potential)；Isoform 7: Cytoplasm (Potential). Tissue Specificity: Detected in normal lung, but also in placenta,liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 is expressed in corneal epithelial cells (at protein level). Isoform 3 is expressed in vascular smooth muscle cells (VSMC). Post-translational modifications: N-glycosylated. Ubiquitinated after VEGFA-mediated autophosphorylation, leading to proteolytic degradation. Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-1169 is important for interaction with PLCG1. Phosphorylation at Tyr-1213 is important for interaction with PIK3R1, PTPN11, GRB2, and PLCG1. Phosphorylation at Tyr-1331 is important for endocytosis and for interaction with CBL, NCK1 and CRK. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.Contains 7 Ig-like C2-type (immunoglobulin-like)domains.Contains 1 protein kinase domain. Database links: Entrez Gene: 2321 Human Entrez Gene: 14254 Mouse Omim: 165070 Human SwissProt: P17948 Human SwissProt: P35969 Mouse Unigene: 594454 Human Unigene: 389712 Mouse Unigene: 10239 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. VEGFR1/Flt1是一種細(xì)胞膜受體激酶，對(duì)血管內(nèi)皮生長(zhǎng)因子有高度的親和性，主要功能是參與血管內(nèi)皮細(xì)胞生長(zhǎng)和血管生成的調(diào)控。用于各種惡性腫瘤的研究。 |
